This work found out that among HR+/HER2- T1-2 N1 M0 breast cancer patients, patients with tumor size >14mm and age >55 as well as patients with 3 PRN, tumor size >14mm and grade worse than well-differentiated could benefit from PMRT. The gene discussed is ERBB2; the disease is breast cancer.